Kyverna Therapeutics, Inc. (KYTX) vs YD Bio Limited Ordinary Shares (YDES)

A side-by-side comparison of Kyverna Therapeutics, Inc. and YD Bio Limited Ordinary Shares across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

KYTX

Kyverna Therapeutics, Inc.

$377M

$6.21HealthcareDelayed quote: Oct 6, 2026, 2:50 PM EDT

YDES

YD Bio Limited Ordinary Shares

$379M

$5.35HealthcareDelayed quote: Oct 6, 2026, 2:50 PM EDT

Total return — KYTX vs YDES

growth of $100 · dividends reinvested · last 1y

KYTX +85.3% (+85.3%/yr)YDES -40.9% (-40.9%/yr)KYTX compounded faster over this window

KYTX YDES

KYTX vs YDES: by the numbers

•YDES is the larger company ($379M vs $377M market cap).
•Both run net losses; KYTX's is the smaller (0.00% vs -1392.61% net margin).

Metrics side by side

Valuation

Metric	KYTX	YDES
P/B ratio	2.28	N/A

Profitability

Metric	KYTX	YDES
Gross margin	0.00%	-7.06%
Operating margin	0.00%	-883.31%
Net margin	0.00%	-1392.61%
ROE	-92.20%	-66.49%
ROIC	-80.67%	N/A

Go deeper

Full KYTX analysis Full YDES analysis Interactive comparison tool

Dig into the metrics

Kyverna Therapeutics ROE YD Bio Limited Ordinary Shares ROE Kyverna Therapeutics operating margin YD Bio Limited Ordinary Shares operating margin Kyverna Therapeutics revenue growth YD Bio Limited Ordinary Shares revenue growth Kyverna Therapeutics free cash flow YD Bio Limited Ordinary Shares free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.